EBOS Updates Market on Lapsing of Performance Rights

EBOS Group Limited ( (AU:EBO) ) has provided an announcement.

EBOS Group Limited has reported that 11,307 performance rights have lapsed, leaving a total of 1,433,288 performance rights currently on issue. The adjustment slightly reduces potential future equity dilution for shareholders and provides updated clarity on the company’s outstanding long-term incentive obligations.

While the change is modest in scale, it reflects the routine management of EBOS’s executive and employee incentive schemes. Investors monitoring capital structure and remuneration alignment will note the updated number of rights as part of their assessment of governance and future share issuance.

The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited is a healthcare and animal care products company listed on both the NZX and ASX. Operating across New Zealand and Australia, it focuses on supplying pharmaceuticals, medical supplies, and related services to pharmacies, hospitals, and other healthcare providers in the region.

Average Trading Volume: 136,505

Technical Sentiment Signal: Sell

Current Market Cap: A$4.29B

For detailed information about EBO stock, go to TipRanks’ Stock Analysis page.